Abstract
Many plants produce enzymes with N-glycosidase activity, also known as Ribosome Inactivating Proteins. These proteins remove a specific adenine residue from the ribosomal RNA (28S in eukaryotes) inducing the block of protein synthesis by inhibiting the binding of the Elongation Factor 2. Both eukaryotic and prokaryotic ribosomes (with different sensitivity) can irreversibly be damaged by the action of these enzymes, suggesting their use as cytotoxic drugs. In fact several applications of targeted N-glycosidases have been developed (i.e. immunotoxins) for the treatment of human diseases such as leukaemia, but biotechnological development has furthermore suggested new applications of targeted N-glycosidases (i.e. Ig192-saporin) that are now used as powerful tools for cell biology research. The high number of enzymes available and the possibility to express these proteins as recombinant products, allow to predict new formulations and applications discussed in this paper starting from the example of the model toxins ricin and saporin.
Keywords: N-glycosidases, Saporin, Ricin, toxins, immunotoxins
Current Chemical Biology
Title: Ricin and Saporin: Plant Enzymes for the Research and the Clinics
Volume: 4 Issue: 2
Author(s): Francesco Giansanti, Luana Di Leandro, Ilias Koutris, Alessio Cialfi, Elisabetta Benedetti, Giulio Laurenti, Giuseppina Pitari and Rodolfo Ippoliti
Affiliation:
Keywords: N-glycosidases, Saporin, Ricin, toxins, immunotoxins
Abstract: Many plants produce enzymes with N-glycosidase activity, also known as Ribosome Inactivating Proteins. These proteins remove a specific adenine residue from the ribosomal RNA (28S in eukaryotes) inducing the block of protein synthesis by inhibiting the binding of the Elongation Factor 2. Both eukaryotic and prokaryotic ribosomes (with different sensitivity) can irreversibly be damaged by the action of these enzymes, suggesting their use as cytotoxic drugs. In fact several applications of targeted N-glycosidases have been developed (i.e. immunotoxins) for the treatment of human diseases such as leukaemia, but biotechnological development has furthermore suggested new applications of targeted N-glycosidases (i.e. Ig192-saporin) that are now used as powerful tools for cell biology research. The high number of enzymes available and the possibility to express these proteins as recombinant products, allow to predict new formulations and applications discussed in this paper starting from the example of the model toxins ricin and saporin.
Export Options
About this article
Cite this article as:
Giansanti Francesco, Di Leandro Luana, Koutris Ilias, Cialfi Alessio, Benedetti Elisabetta, Laurenti Giulio, Pitari Giuseppina and Ippoliti Rodolfo, Ricin and Saporin: Plant Enzymes for the Research and the Clinics, Current Chemical Biology 2010; 4 (2) . https://dx.doi.org/10.2174/2212796811004020099
DOI https://dx.doi.org/10.2174/2212796811004020099 |
Print ISSN 2212-7968 |
Publisher Name Bentham Science Publisher |
Online ISSN 1872-3136 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Composite Lymphomas: A Challenging Entity
Current Cancer Therapy Reviews The mTOR/4E-BP1/eIF4E Signalling Pathway as a Source of Cancer Drug Targets
Current Medicinal Chemistry Editorial (Hot Topic Potential Value and Limitation of Dual Inhibitors of PI3K and mTOR in the Treatment of Cancer)
Current Cancer Drug Targets The Interaction of NK Cells and Dendritic Cells in the Tumor Environment: How to Enforce NK Cell & DC Action Under Immunosuppressive Conditions?
Current Medicinal Chemistry Advances and Challenges in the Synthesis of Highly Oxidised Natural Phenols with Antiviral, Antioxidant and Cytotoxic Activities
Current Medicinal Chemistry Epidemiology of Candida albicans Infections and Role of Non-Candidaalbicans Yeasts
Current Drug Targets Cytoplasmic CXCR4 High-Expression Exhibits Distinct Poor Clinicopathological Characteristics and Predicts Poor Prognosis in Triple-Negative Breast Cancer
Current Molecular Medicine Clinical Pharmacotherapy and Drug Development for Pulmonary Arterial Hypertension
Recent Patents on Cardiovascular Drug Discovery Development of Fourth Generation ABC Inhibitors from Natural Products: A Novel Approach to Overcome Cancer Multidrug Resistance
Anti-Cancer Agents in Medicinal Chemistry Cyclin-Dependent Kinase 4/6 (Cdk4/6) Inhibitors: Perspectives in Cancer Therapy and Imaging
Mini-Reviews in Medicinal Chemistry Immune Therapy of Multiple Sclerosis - Future Strategies
Current Pharmaceutical Design Lipid-Based Nanoparticulate Systems for the Delivery of Anti-Cancer Drug Cocktails: Implications on Pharmacokinetics and Drug Toxicities
Current Drug Metabolism Biofunctional Peptides from Milk Proteins: Mineral Binding and Cytomodulatory Effects
Current Pharmaceutical Design Global Gene Expression in Classification, Pathogenetic Understanding and Identification of Therapeutic Targets in Acute Myeloid Leukemia
Current Pharmaceutical Biotechnology Nutrition Support of Patients Undergoing Hematopoietic Stem Cell Transplantation (HSCT)
Current Nutrition & Food Science Epigenetic Regulation of ABCB1 Transporter Expression and Function
Current Pharmacogenomics and Personalized Medicine DYRK1A Kinase Inhibitors with Emphasis on Cancer
Mini-Reviews in Medicinal Chemistry MICA Molecules in Disease and Transplantation, a Double-Edged Sword?
Current Immunology Reviews (Discontinued) Interferon alpha for Treatment of Chronic Myeloid Leukemia
Current Drug Targets Stem Cell Genetic Therapy for Fanconi Anemia – A New Hope
Current Gene Therapy